Merck, BeiGene team up for BRAF inhibitor
DARMSTADT, Germany—Merck Serono, a division of Merck, has entered into a global licensing, co-development and commercialization agreement with BeiGene Co. Ltd. for BeiGene-283, a second-generation BRAF inhibitor for the treatment of cancer. Per the terms of the agreement, BeiGene will be responsible for developing and commercializing the compound in the People's Republic of China while Merck will be responsible for development and commercialization in the rest of the world. Merck will pay BeiGene an undisclosed amount up front, and BeiGene will be eligible for further payments if clinical development milestones are reached in the People's Republic of China and the rest of the world. BeiGene also stands to receive commercial milestones and up to double-digit royalties on net sales. BeiGene-283 is expected to enter clinical development next year.